CCK-8 Restores Morphine-Impaired Hippocampal LTP

Opioid exposure can alter neuronal plasticity as well as behavior. In the reference study, Wen and colleagues examined whether cholecystokinin-octapeptide, commonly called CCK-8, could counteract the inhibitory effect of morphine on hippocampal long-term potentiation (LTP). The work is important because it moved beyond a general observation that CCK peptides influence learning and memory: it tested a defined synaptic endpoint and used receptor-selective antagonists to identify the signaling subtype involved. The complete report is available in Neuroscience Letters.

Study Background and Research Question

LTP is a persistent increase in synaptic efficacy produced by patterned stimulation and is widely used to study the cellular basis of learning-related plasticity. The hippocampus is particularly relevant because morphine exposure has been associated with impaired memory processing and reduced plasticity in this region. The authors focused on the lateral perforant path (LPP) to dentate gyrus (DG) granule-cell synapse, a circuit in which changes in evoked population spikes can be measured electrophysiologically.

CCK is a brain–gut peptide present in multiple molecular forms. CCK-8 is prominent in the central nervous system and can regulate transmitter release and neuronal excitability through two major G protein-coupled receptor subtypes: CCK1 and CCK2. Previous work cited by the authors had connected CCK-8 with morphine-related amnesia and hippocampal spine-density changes, but its effect on morphine-disrupted LTP had not been established. The central research question was therefore twofold: can CCK-8 restore hippocampal LTP after morphine treatment, and which CCK receptor subtype mediates that effect?

Key Innovation from the Reference Study

The study’s main innovation was the combination of an opioid-induced synaptic plasticity model with receptor-subtype pharmacology. Rather than inferring memory improvement only from behavioral performance, the investigators recorded population spikes in the DG after high-frequency stimulation. This design allowed them to ask whether CCK-8 directly normalized a physiological correlate of synaptic strengthening.

The experimental logic also separated enhancement from restoration. CCK-8 was tested in saline-treated rats to determine whether it could augment otherwise intact LTP, and in morphine-treated rats to determine whether it could reverse an induced deficit. Finally, the CCK2 antagonist L365,260 and the CCK1 antagonist L-364,718 were used as mechanistic probes. The resulting pattern—loss of CCK-8 enhancement with CCK2 blockade but not CCK1 blockade—provided stronger evidence for CCK2-dependent regulation than a peptide treatment alone would have supplied.

Methods and Experimental Design Insights

The investigators used male Wistar rats and recorded LPP-evoked population spikes in the dentate gyrus. The study included 224 animals, with rats weighing 180 ± 10 g on arrival; housing conditions included a temperature of 21 ± 2 °C, approximately 60% humidity, and a 12-hour light–dark cycle, as reported in the original methods. These details matter because animal age, handling, circadian timing, and physiological state can influence hippocampal excitability and the magnitude of LTP.

Morphine hydrochloride was administered subcutaneously at 30 mg/kg to produce the acute opioid condition. Control animals received saline at 1 ml/kg. CCK-8 was delivered intracerebroventricularly at 0.1 or 1 μg. The receptor experiments used intracerebroventricular L365,260 or L-364,718 at 10 μg before CCK-8 administration. LTP was induced by high-frequency stimulation of the LPP, and the subsequent population-spike response in the DG served as the primary electrophysiological readout.

Protocol Parameters

• Animal model: Male Wistar rats were acclimated for at least 5 days before testing; the reported study used 224 animals and maintained controlled housing conditions.
• Morphine condition: Acute morphine was administered subcutaneously at 30 mg/kg, while saline controls received 1 ml/kg, according to the reference protocol.
• CCK-8 treatment: Intracerebroventricular doses of 0.1 and 1 μg were used to test enhancement in saline-treated animals; 1 μg was used in the principal morphine-restoration comparison.
• Receptor dissection: L365,260, a CCK2 receptor antagonist, and L-364,718, a CCK1 receptor antagonist, were each administered intracerebroventricularly at 10 μg before CCK-8 in the antagonist experiments.
• Electrophysiology: LPP stimulation and DG population-spike recording were used to quantify HFS-induced LTP rather than relying on a behavioral memory assay.

For replication, the most important design principle is not simply the nominal peptide dose. It is the matched comparison among saline, morphine, CCK-8, and antagonist-plus-CCK-8 groups, together with consistent stimulation and recording conditions. Because the study used central administration in anesthetized or acutely prepared animals, its doses should not be transferred directly to peripheral, cellular, or behavioral protocols.

Core Findings and Why They Matter

Acute morphine significantly attenuated hippocampal LTP in the LPP–DG pathway. This result supports the use of morphine exposure as a model of opioid-sensitive disruption of synaptic plasticity, although it does not by itself establish the molecular cause of the impairment.

CCK-8 had two related effects. In saline-treated rats, both 0.1 and 1 μg CCK-8 significantly augmented LTP. In morphine-treated rats, 1 μg CCK-8 restored the population-spike response that had been reduced by morphine. Thus, the peptide was not merely inactive under opioid exposure; at the effective dose it recovered a measurable form of synaptic strengthening.

The antagonist experiments supplied the key mechanistic result. Pretreatment with L365,260 reversed the enhancement produced by CCK-8, whereas L-364,718 did not. Within the limits of pharmacological specificity, this indicates that the LTP-promoting and morphine-attenuating actions of CCK-8 were mediated predominantly through CCK2 receptors. The findings therefore support describing the effect as CCK2-dependent rather than broadly attributing it to all CCK receptors.

These observations matter for two reasons. First, they connect a neuropeptide signal to a defined electrophysiological consequence of morphine exposure. Second, they offer a mechanistic bridge between earlier reports of CCK-8-associated improvements in morphine-related memory impairment and a synaptic substrate that could contribute to those behavioral effects. The current experiment did not directly measure memory, addiction-like behavior, or neuronal survival, so the strongest conclusion is that CCK-8 can normalize morphine-sensitive hippocampal LTP under the tested conditions.

Comparison with Existing Internal Articles

The internal overview Cholecystokinin Octapeptide Restores Morphine-Impaired LTP in Rats reaches the same central interpretation: CCK-8 reverses a morphine-associated LTP deficit through CCK2 receptor activation. Its value is rapid orientation, whereas the reference paper is necessary for evaluating the animal model, intracerebroventricular dosing, stimulation pathway, electrophysiological endpoint, and antagonist controls.

A second internal resource, Cholecystokinin Octapeptide Ammonium: A Precision Tool for Immune Modulation and Neurobiology, places CCK-8 in a broader neurobiological and immune-signaling context. That broader scope may help researchers identify related assay concepts, but it should not be treated as additional evidence for the specific LPP–DG LTP result. The reference study establishes a receptor-defined synaptic effect in rats; it does not validate every reported action of CCK-8 in other tissues or disease models.

Limitations and Transferability

Several limitations constrain interpretation. The model used acute morphine exposure, not the repeated dosing, withdrawal, or self-administration paradigms that more closely represent opioid dependence. Consequently, the data demonstrate protection or restoration of LTP after an acute challenge, but they do not prove that CCK-8 prevents addiction, reverses established dependence, or improves cognition in opioid-use disorder.

The study also relied on population spikes from one hippocampal pathway. This is a useful systems-level readout, but it does not identify whether CCK2 activation acts presynaptically, postsynaptically, through interneurons, or through changes in glutamatergic and opioid signaling. Pharmacological antagonists strengthen the receptor assignment, yet genetic receptor deletion or complementary intracellular measurements would provide a more definitive causal test.

Formulation and route are additional transferability issues. The paper used centrally administered CCK-8, whereas experiments with Cholecystokinin octapeptide ammonium may involve a different salt form, preparation procedure, route, and exposure profile. Researchers should establish peptide integrity, concentration, vehicle compatibility, and receptor activity in their own system rather than assume that a nominal mass dose produces equivalent central exposure.

Why this cross-domain matters, maturity, and limitations

CCK-8 is often discussed in connection with diverse endpoints, including inhibition of apoptosis in neuronal cells, modulation of immune responses, anxiety-like behavior induction in zebrafish, and promotion of atrial natriuretic peptide secretion. Those endpoints belong to different experimental domains and should not be inferred from the present rat LTP study. In particular, the reference paper did not test neuronal apoptosis, immune-cell activity, zebrafish behavior, or cardiac hormone release.

The mature conclusion from this paper is narrower and more useful: CCK-8 enhanced hippocampal LTP in saline-treated rats and restored morphine-impaired LTP through a pharmacologically CCK2-dependent mechanism. Extending that conclusion to other tissues requires independent evidence, appropriate receptor controls, and species- and route-specific dose optimization. Keeping these domains separate prevents a plausible receptor mechanism from being mistaken for universal biological activity.

Research Support Resources

Researchers can use Cholecystokinin octapeptide ammonium (CCK-8 ammonium, SKU C8717) to support related peptide workflows. The product information describes the sulfated ammonium salt and recommends sealed, dry, light-protected storage at −20 °C under nitrogen; formulation, solubility, route, and dose equivalence should be verified experimentally before adapting the intracerebroventricular conditions reported in the reference study.